Companies/Organogenesis Holdings Inc.

Company profile

Organogenesis Holdings Inc.

NASDAQ: ORGO · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Canton, MACIK 0001661181Reports USD

#203 of 1,394 Healthcare companies by revenue63rd-percentile growth

EA Score

65B

FH 73DQ 62GM 48SS 68

v0.1 · 65/100 weight · provisional

↑ return on assets, workforce scale · ↓ Piotroski F, growth stability

Methodology →

Revenue TTM

$513.6M

Rev growth YoY (TTM)

+11.9%

Net income (FY)

$37.0M

Employees

869

Market cap

$303.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$564.2M$564.2M2025

Net income$37.0M$37.0M2025

Operating income$44.7M$44.7M2025

Total assets$598.7M$598.7M2025

Liabilities$164.8M$164.8M2025

Equity$300.1M$300.1M2025

Revenue trend

FY2019 – FY2025 · USD

$261.0M

FY19

$338.3M

FY20

$468.1M

FY21

$97.1M

FY22

$450.9M

FY22

$433.1M

FY23

$482.0M

FY24

$564.2M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product100%

Grant0%

By geography

Not disclosed.

The read

Organogenesis Holdings Inc. booked $564.2M in FY2025 revenue, growing 17% year over year — faster than most Healthcare companies we track, at a 6.6% net margin.

Peers · Healthcare

Fennec Pharmaceuticals Inc.61C Palatin Technologies, Inc.41D Entrada Therapeutics, Inc.46D OraSure Technologies, Inc.67B

Key facts

CEOGary S. Gillheeney

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersCanton, MA

ExchangeNASDAQ: ORGO

Employees869

IPO date2017-01-05

Latest filings

8-K2026-06-16 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-30 10-K2026-02-26 8-K2026-02-26 8-K2026-02-23 8-K2025-12-29

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.